Perioperative Pregabalin in Ureteroscopy: a Pilot

• Status: Completed
• Trial end date: 2020-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose a pilot clinical trial on the use of perioperative pregabalin in order to decrease ureteral stent related symptoms and decrease opioid usage after ureteroscopy with stent placement. Patients undergoing ureteroscopy with stent placement will receive a single dose of 300 mg pregabalin PO in the preoperative area. This work will assess safety and feasibility of studying this regimen at our institution, with the aim of performing a randomized, placebo-controlled, double-blinded study in the future.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Missouri-Columbia
• Treatments: Pregabalin

Criteria

Subject Population Undergoing elective ureteroscopy with stent placement by Dr. Murray at University of Missouri Hospital and affiliated facilities

Subject Inclusion

Age >= 18 years

Subject Exclusion

• Renal insufficiency (eGFR < 30 mL/minute/1.73 m2)

• Chronic indwelling ureteral stent

• Chronic opioid use

• History of opioid abuse

• Chronic gabapentinoid use

• Plan for inpatient hospitalization

• Pregnancy

• Inability of the patient to consent for themselves in English

• Allergy to gabapentinoid

• Liver failure or hepatic dysfunction